Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Trastuzumab (original brand name Herceptin) is a targeted monoclonal antibody therapy used primarily to treat HER2-overexpressing cancers, including HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab (original brand name Herceptin) is a targeted monoclonal antibody therapy used primarily to treat HER2-overexpressing cancers, including HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.